Structure Therapeutics Inc. American Depositary Shares (GPCR) Stock Forecast & Price Target
Structure Therapeutics Inc. American Depositary Shares · NASDAQ
$47.72-0.97 (-1.99%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Structure Therapeutics Inc. American Depositary Shares, 11 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $70.00 to $140.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $105.00 sits 120% above the current $47.72. The rating mix has stayed broadly stable, with Buy-side ratings easing from 12 to 11 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-2.08 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy11100%
Hold00%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Structure Therapeutics Inc. American Depositary Shares.
As of Jul, 11 of 11 firms rate GPCR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GPCR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.49 – $2.03 · 10 analysts · -49% YoY
Next period, 10 analysts expect Structure Therapeutics Inc. American Depositary Shares to earn $-0.19 a share (range $-0.49 – $2.03), versus $-0.37 a year earlier. Full-year consensus is $-1.43, growing to $-2.08 the year after.
REVENUE · NEXT QUARTER
$50.0M
Range $0 – $500.0M · 10 analysts
Revenue is expected to reach $50.0M (range $0 – $500.0M). Full-year consensus is $38.5M, rising to $41.7K next year.
Top analysts covering Structure Therapeutics Inc. American Depositary Shares
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GPCR.
#1
Andrew Fein
HC Wainwright & Co. · Rank #35
Buy
$75.00+57.2% to target
Overall win rate
46%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #38
Buy
$113.00+136.8% to target
Overall win rate
44%
+ Follow
#3
Yasmeen Rahimi
Piper Sandler · Rank #152
Buy
$93.00+94.9% to target
Overall win rate
34%
+ Follow
#4
AG
Ananda Ghosh
HC Wainwright & Co.
Buy
$70.00+46.7% to target
Coverage
—
+ Follow
#5
Seamus Fernandez
Guggenheim
Buy
$140.00+193.4% to target
Coverage
—
+ Follow
GPCR stock forecast FAQ
What is GPCR's average 12-month price target?+
The 11 analysts with a live target average $105.00 for Structure Therapeutics Inc. American Depositary Shares over the next 12 months, ranging from a $140.00 high to a $70.00 low.
Is GPCR stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 11 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GPCR?+
The Street-high target is $140.00 (Guggenheim), and the Street-low is $70.00 (HC Wainwright & Co.). The average of all 11 active targets is $105.00.
How many Wall Street analysts cover GPCR?+
11 analysts have an active rating on Structure Therapeutics Inc. American Depositary Shares, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering GPCR?+
Among analysts who currently cover GPCR, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #35). Their current call is Buy with a $75.00 target.
What is Structure Therapeutics Inc. American Depositary Shares's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.49 – $2.03) across 10 analysts. Full-year EPS is projected at $-1.43, rising to $-2.08 the following year.
How much revenue is Structure Therapeutics Inc. American Depositary Shares expected to report next quarter?+
Consensus revenue is $50.0M (range $0 – $500.0M). Full-year revenue is projected at $38.5M, growing to $41.7K next year.
Have analysts been upgrading or downgrading GPCR lately?+
As of Jul, 11 of 11 firms rate GPCR a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GPCR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
